Praxis Precision Medicines, Inc. - Common Stock (PRAX)
162.71
+105.36 (183.71%)
NASDAQ · Last Trade: Oct 16th, 9:25 PM EDT
Via Benzinga · October 16, 2025
Via Benzinga · October 16, 2025
The company is working on a treatment for essential tremor. Positive results shocked investors following a negative readout in February.
Via Investor's Business Daily · October 16, 2025
Via Benzinga · October 16, 2025
Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today?stocktwits.com
Via Stocktwits · October 16, 2025

Via Benzinga · March 3, 2025
Via Benzinga · October 16, 2025
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · October 16, 2025
Via Benzinga · October 16, 2025
Praxis stock jumps after Phase 3 trials show ulixacaltamide significantly improves essential tremor symptoms and meets key efficacy endpoints.
Via Benzinga · October 16, 2025
Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures.
Via Benzinga · August 4, 2025
Praxis Precision Medicines (PRAX) reports Q2 2025 results, highlighting strong clinical data for epilepsy drug vormatrigine with 56.3% seizure reduction. EPS beats estimates, stock rises pre-market.
Via Chartmill · August 4, 2025
Via Benzinga · August 1, 2025
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Via Investor's Business Daily · July 10, 2025
Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine.
Via Benzinga · May 7, 2025
Via Benzinga · May 7, 2025
Via Benzinga · May 1, 2025
Via Benzinga · April 8, 2025

Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.
Via Benzinga · March 3, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Via Chartmill · February 28, 2025

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · February 28, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Via Chartmill · February 28, 2025